Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia
Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia
复制标题
DOI：
10.1136/bjo.2006.096776
复制
发表时间：
2007-02-01
影响因子：
4.1
通讯作者：
Duker, Jay S.
中科院分区：
文献类型：
--
作者：
Yamamoto, Izumi;Rogers, Adam H.;Duker, Jay S.
目的：评价玻璃体内注射贝伐单抗（Avastin）治疗病理性近视所致黄斑中心凹下脉络膜新生血管（CNV）的安全性和有效性。方法：回顾性分析2005年8月至2006年1月在美国马萨诸塞州波士顿新英格兰眼科中心接受玻璃体内注射贝伐单抗1.25 mg治疗的原发性或复发性黄斑中心凹下继发于近视的CNV患者的临床资料。收集临床检查、眼底照相、荧光素血管造影、光学相干断层扫描及视力等资料。11只眼中有5只眼曾接受过光动力学治疗。注射前6只眼的视力测量值为20/50至20/100，5只眼为20/200或更差。平均随访153天（范围35-224天）后，7只眼的注射后视力为20/20至20/40，1只眼为20/50至20/100，3只眼为20/200或更差。三只眼睛接受两次贝伐珠单抗注射，八只眼睛接受一次注射。视力平均提高+3.5（范围-1至+8行）行，11只眼中有8只在末次随访时达到20/50或更好。中央凹厚度从340（范围253-664）μ m改善至234（范围142-308）μ m，代表平均减少103（范围+4至-356）μ m。没有注射并发症或药物相关的副作用observed.Conclusions：在这一小系列的眼睛有限的后续行动，玻璃体内贝伐单抗似乎是安全的，并可能有效的眼睛与黄斑下CNV继发于病理性近视。
Objective: To evaluate the safety and efficacy of intravitreal bevacizumab ( Avastin) as treatment for subfoveal choroidal neovascularisation ( CNV) due to pathological myopia.Methods: Consecutive series of primary or recurrent subfoveal CNV secondary to myopia treated with intravitreal bevacizumab 1.25 mg between August 2005 and January 2006 at the New England Eye Center, Boston, Massachusetts, USA, were reviewed retrospectively. Data from clinical examination, fundus photography, fluorescein angiography, optical coherence tomography and visual acuity were collected.Results: There were 11 eyes of 9 patients. 5 of 11 eyes had been treated previously with photodynamic therapy. Pre-injection visual acuity measured 20/50 to 20/100 in 6 eyes and 20/200 or worse in 5 eyes. After a mean follow-up of 153 ( range 35-224) days, post-injection visual acuity measured 20/20 to 20/40 in 7 eyes, 20/50 to 20/100 in 1 eye and 20/200 or worse in 3 eyes. Three eyes received two bevacizumab injections and eight eyes received one injection. Visual acuity improved by a mean of +3.5 ( range -1 to +8 lines) lines, and 8 of 11 eyes achieved 20/50 or better at the last follow-up. Central foveal thickness improved from 340 ( range 253-664) mu m to 234 ( range 142-308) mu m, representing an average reduction of 103 ( range +4 to -356) mu m. No injection complications or drug-related side effects were observed.Conclusions: In this small series of eyes with limited follow-up, intravitreal bevacizumab seems to be safe and potentially efficacious in eyes with subfoveal CNV secondary to pathological myopia.